secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2023-10-03T23:59:59+00:00
Accession:  0001193125-23-249487
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron and Intellia expand CRISPR collaboration to neurological and muscular diseases
--------------------------------------------------------------------------------

- Uses Regeneron's antibody-targeted AAV vectors and Intellia's Nme2CRISPR/Cas9 for in vivo delivery.
- Initial research on two non-liver targets for neurological and muscular diseases.
- Each company may lead development/commercialization for one target; co-development option available.
- Builds on existing successful collaboration between the two firms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312523249487/0001193125-23-249487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312523249487/d556975d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-249487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer